Profiles of individual research compounds and peptides — mechanism, the published evidence base, and how each is studied alongside incretin therapy. Research-grade compounds referenced are sold strictly for laboratory and in-vitro use only.
A contract research lab tracking a multi-week in-vitro binding assay lost an $18,000 reference-standard batch of a GLP-1 analog because a supplier shipment sat at ambient temperature for 36 hours…
A Vial That Didn't Add Up A lab coordinator running peptide handling for a sports-performance research program pulled the quarterly inventory log and found a gap that didn't reconcile. Forty vials…
The Vial That Never Should Have Shipped Warm A research lab ordering a "GLP-3 peptide" for a stability comparison ran into the same problem twice in one quarter: the product arrived at ambient…
A research lab technician reconstitutes a lyophilized peptide vial at 9 a.m., logs the storage temperature, and by 2 p.m. is fielding a question from a PI who wants to know whether the receptor…
A clinic operator running a medical weight-management practice with 300 active patients gets the same question every week from staff sourcing research materials: "the supplier calls this a GLP-3…
A research lab orders three vials of the same GLP-3 peptide analog from three different suppliers to run a head-to-head stability comparison. Same nominal dose, same generic compound name on the…
A weight-management clinic running three treatment rooms and a Friday-afternoon walk-in slot loses refrigeration over a long weekend. By Monday, forty vials of GLP-1 receptor agonist sat between…
The clinical and research communities now have two structurally related but pharmacologically distinct peptide compounds capable of producing weight reductions that approach or exceed 20% of body…
A weight management clinic enrolling 40 consecutive patients on semaglutide 2.4 mg (Wegovy) in 2022 saw outcomes closely tracking the 14.9% mean body weight reduction reported in STEP 1 — a…
The Problem Nobody Talks About When Patients Start GLP-1 Therapy A 52-year-old male patient starts semaglutide at 0.25 mg/week. By week 12, he's down 18 pounds — but he's also reporting a nagging…